Rayburn B K, Bourge R C
University of Alabama at Birmingham, Birmingham, AL, USA.
Rev Cardiovasc Med. 2001;2 Suppl 2:S25-31.
Nesiritide is the generic name for recombinant human B-type natriuretic peptide. This drug represents the first of a new class of agents for the treatment of decompensated congestive heart failure. The properties of B-type natriuretic peptide include a balanced arterial and venous vasodilatation and a marked natriuresis and diuresis, making it an excellent drug for the management of heart failure. We review the physiology and pathophysiology of the natriuretic peptides and the clinical data for nesiritide. In addition, the hemodynamic effects of the drug as well as its efficacy and safety in the treatment of heart failure are critiqued. Nesiritide is a new class of therapeutic peptide for the treatment of heart failure that appears to offer unique and safe hemodynamic properties.
奈西立肽是重组人B型利钠肽的通用名称。这种药物代表了用于治疗失代偿性充血性心力衰竭的一类新型药物中的首个药物。B型利钠肽的特性包括平衡的动静脉血管舒张以及显著的利钠和利尿作用，使其成为治疗心力衰竭的理想药物。我们综述了利钠肽的生理学和病理生理学以及奈西立肽的临床数据。此外，还对该药物的血流动力学效应及其在心力衰竭治疗中的疗效和安全性进行了评价。奈西立肽是一种用于治疗心力衰竭的新型治疗性肽，似乎具有独特且安全的血流动力学特性。
